1. Home
  2. HAFN vs ACAD Comparison

HAFN vs ACAD Comparison

Compare HAFN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hafnia Limited

HAFN

Hafnia Limited

HOLD

Current Price

$7.66

Market Cap

3.7B

Sector

N/A

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.44

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAFN
ACAD
Founded
2012
1993
Country
Singapore
United States
Employees
4876
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.3B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
HAFN
ACAD
Price
$7.66
$25.44
Analyst Decision
Buy
Analyst Count
0
22
Target Price
N/A
$30.55
AVG Volume (30 Days)
1.2M
1.3M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
6.21%
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
N/A
$18.80
Revenue Next Year
N/A
$11.70
P/E Ratio
$11.39
$1,327.00
Revenue Growth
N/A
40.45
52 Week Low
$5.17
$19.69
52 Week High
$9.54
$28.35

Technical Indicators

Market Signals
Indicator
HAFN
ACAD
Relative Strength Index (RSI) 56.17 54.10
Support Level $7.16 $25.00
Resistance Level $7.73 $27.79
Average True Range (ATR) 0.16 0.75
MACD 0.05 -0.08
Stochastic Oscillator 80.18 52.73

Price Performance

Historical Comparison
HAFN
ACAD

About HAFN Hafnia Limited

Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Company manages it's business through the following reporting segments: LR2 tankers, LR1 tankers, MR tankers, Handy tankers.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: